title: Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
abstract: BACKGROUND
  This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy.
  
  
  METHODS
  Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS).
  
  
  RESULTS
  The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups.
  
  
  CONCLUSIONS
  In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.
authors.affiliation: Department of Radiology, Tokyo Medical Center, National Hospital Organization, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. tohashi@ntmc.hosp.go.jp
authors.forename: Toshio
authors.initials: T
authors.lastname: Ohashi
authors.forename: Atsunori
authors.initials: A
authors.lastname: Yorozu
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Toya
authors.forename: Shiro
authors.initials: S
authors.lastname: Saito
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Momma
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods; D011467:Prostate / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D011829:Radiation Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D012107:Research Design; D014555:Urination Disorders / Q000139:chemically induced / Q000209:etiology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007457:Iodine Radioisotopes; D007987:Gonadotropin-Releasing Hormone